Project Grant HT94252310276
Award Date
4/1/23
Completion Date
3/31/26
Dollars Obligated
$495K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This Project Grant award from the Defense Health Agency provides $377,681 to the University of Cambridge for research elucidating and targeting clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The award period runs from April 1, 2023 through March 31, 2026. The research funded under this award directly supports the Military Medical Research and Development program's goal of investigating medical solutions for the...
The University of Cambridge will receive $439,922 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from September 2022 through September 2025 to dissect ovarian cancer tumor-immune microenvironments through 3D in situ molecular profiling. The Military Medical Research and Development program aims to transform military and public health through innovative medical research...
The University of Cambridge received a $824,548 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the role of hypoxia in vasculogenic mimicry, response to therapy, and metastasis. This 3-year grant awarded on May 1, 2024 will support basic, translational, and clinical research to advance scientific understanding and develop new treatments in areas such as cancer, neurological...
The University of Cambridge received a $1,996,828.00 four-year Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop predictive models for treatment response, early relapse, and survival in breast cancer across molecular subtypes. The University will leverage multi-modal data integration techniques to explore early signals of later metastatic recurrence. This research aims to...
The University of Cambridge received a $4,598,677 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development program (CFDA 12.420). The research aims to use multi-modal data integration across breast cancer molecular subtypes to develop predictors of treatment response, early relapse, and survival, as well as explore early signals of later metastatic recurrence. The 4-year grant, which began on September 1, 2023, leverages the...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
This $1,014,000 project grant from the Defense Health Agency will fund research into targeted therapeutic opportunities for ovarian clear cell, small cell, and endometrioid carcinomas at President And Fellows of Harvard College from May 1, 2023 to April 30, 2027. The grant falls under the Military Medical Research and Development program, which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions. Through this...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of the Army Medical Command awarded a $248,250 Project Grant to Microquin LTD on June 1, 2022 to support the development of a first-in-class therapeutic to treat epithelial ovarian cancer. The work will be performed in Cambridge, MA from June 1, 2022 through May 31, 2023. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research with the goals of transforming military and...